Product Description
Exametazime is a diagnostic radiopharmaceutical agent commonly used for the preparation of Tc99m Exametazime injection. It acts as a chelating agent for the radioisotope technetium-99m to form a cationic complex. It is used in the detection of altered regional cerebral perfusion and for the radiolabeling of autologous leukocytes. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Exametazime)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Bulgaria | Canada | Colombia | Czech | Finland | France | Greece | Hong Kong | Hungary | Indonesia | Ireland | Israel | Korea | Lithuania | Malta | Netherlands | Peru | Portugal | Slovenia | South Africa | Sweden | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/25/2020 |
News Article |
BWXT Successfully Demonstrates Labeling of Cold Kits with its Mo-99 / Tc-99m Technology |
|
01/27/2020 |
News Article |
Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime® |